- Home
- PCB vs SGHT Comparison
PCB vs SGHT Comparison
Compare PCB & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCB
- SGHT
- Stock Information
- Founded
- PCB 2003
- SGHT 2011
- Country
- PCB United States
- SGHT United States
- Employees
- PCB N/A
- SGHT N/A
- Industry
- PCB Major Banks
- SGHT Medical Specialities
- Sector
- PCB Finance
- SGHT Health Care
- Exchange
- PCB Nasdaq
- SGHT Nasdaq
- Market Cap
- PCB 285.3M
- SGHT 304.4M
- IPO Year
- PCB N/A
- SGHT 2021
- Fundamental
- Price
- PCB $20.23
- SGHT $3.56
- Analyst Decision
- PCB Hold
- SGHT Buy
- Analyst Count
- PCB 2
- SGHT 7
- Target Price
- PCB $22.00
- SGHT $6.27
- AVG Volume (30 Days)
- PCB 28.3K
- SGHT 218.9K
- Earning Date
- PCB 01-23-2025
- SGHT 11-07-2024
- Dividend Yield
- PCB 3.56%
- SGHT N/A
- EPS Growth
- PCB N/A
- SGHT N/A
- EPS
- PCB 1.68
- SGHT N/A
- Revenue
- PCB $94,833,000.00
- SGHT $79,543,000.00
- Revenue This Year
- PCB N/A
- SGHT $2.13
- Revenue Next Year
- PCB $10.34
- SGHT $7.99
- P/E Ratio
- PCB $12.04
- SGHT N/A
- Revenue Growth
- PCB N/A
- SGHT N/A
- 52 Week Low
- PCB $14.50
- SGHT $3.30
- 52 Week High
- PCB $22.20
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- PCB 41.74
- SGHT 39.52
- Support Level
- PCB $19.09
- SGHT $3.45
- Resistance Level
- PCB $20.63
- SGHT $3.64
- Average True Range (ATR)
- PCB 0.58
- SGHT 0.19
- MACD
- PCB -0.25
- SGHT 0.03
- Stochastic Oscillator
- PCB 36.01
- SGHT 31.90
About PCB PCB Bancorp
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.